Oppenheimer starts Monopar with Outperform on ALXN1840 potential

Oppenheimer initiated coverage of Monopar Therapeutics (MNPR) with an Outperform rating and $77 price target The company acquired ALXN1840 from AstraZeneca in October 2024 “with the goal of bringing it back to life,” the analyst tells investors in a research note. The firm believes Monopar has a “compelling opportunity” to show regulators that the data-to-date support ALXN1840’s differentiated mechanism by addressing flaws in the previous study design and analysis around copper excretion. It believes ALXN1840 can address limitations with standard of care in Wilson disease patients.